Display options
Cite
Kneppelhout JC, Mulder CJ, van Berge Henegouwen GP, et al. Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease. Neth J Med. 1992;41(1):11-6
Kneppelhout, J. C., Mulder, C. J., van Berge Henegouwen, G. P., de Vries, R. A., & Brandt, K. H. (1992). Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease. The Netherlands journal of medicine, 41(1), 11-6.
Kneppelhout, J C, et al. "Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease." The Netherlands journal of medicine vol. 41,1 (1992): 11-6.
Kneppelhout JC, Mulder CJ, van Berge Henegouwen GP, de Vries RA, Brandt KH. Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease. Neth J Med. 1992 Aug;41(1):11-6. PMID: 1407234.
Copy Download .nbib Format: NLM
Share it on

Neth J Med. 1992 Aug;41(1):11-6.

Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease.

The Netherlands journal of medicine

J C Kneppelhout, C J Mulder, G P van Berge Henegouwen, R A de Vries, K H Brandt

Affiliations

  1. Department of Hepato-gastroenterology, Free University Hospital Amsterdam, Netherlands.

PMID: 1407234

Abstract

We studied the effect of ursodeoxycholic acid in 19 patients with primary biliary cirrhosis, mainly stages III and IV. The dose of UDCA employed was 10-15 mg/kg body weight per day. After 1 yr, 17 patients were still using UDCA, and the mean values of serum alkaline phosphatase, gamma-glutamyltranspeptidase and alanine-aminotransferase had fallen significantly. Serum bilirubin, initially elevated in 7 of the 13 late-stage (III and IV) patients, showed a further increase in 3 of the 7 patients. In 2 of these 3 patients, UDCA had to be withdrawn (dose reduction had no effect). One patient developed a decompensated cirrhosis in spite of UDCA withdrawal. Pruritus worsened in 4 patients, all of whom were late stage patients. Ten late-stage (III-IV) patients showed improvement in liver biochemistry and clinical findings as did all early-stage PBC patients. Thus, UDCA treatment is not beneficial for all PBC patients. Special care should be taken in the early phase of UDCA therapy in later-stage (III-IV) patients: frequent biochemical checks should be carried out, for instance every 2 weeks in the first 2 months after starting UDCA, especially the estimation of bilirubin.

Similar articles

Show all 7 similar articles

Substances

MeSH terms

Publication Types

LinkOut - more resources